查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1771462

美國獸醫神經退化性疾病診斷市場：市場規模、佔有率、趨勢分析（按診斷測試、動物類型、產品類型、適應症、最終用途）、細分市場預測（2025-2030 年）

U.S. Veterinary Neurodegenerative Disease Diagnostics Market Size, Share & Trends Analysis Report By Diagnostic Tests, By Animal Type, By Product, By Indication, By End-use, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

美國獸醫神經退化性疾病診斷市場的成長與趨勢

根據 Grand View Research, Inc. 的新報告，美國獸醫神經退化性疾病診斷市場預計到 2030 年將達到 1.5844 億美元，2025 年至 2030 年的複合年成長率為 7.3%。

推動市場成長的主要因素包括研究舉措的不斷擴展、神經退化性疾病盛行率的上升以及倡導舉措的不斷推進。犬類認知功能障礙 (CCD) 和貓科動物認知功能障礙 (FCD) 等疾病正得到越來越廣泛的關注，研究表明，近 73% 的老年犬和 50% 的老年貓出現認知能力下降的徵兆。寵物飼主和獸醫的這種意識不斷增強，推動了對早期精準診斷工具的需求。

技術創新正在推動該領域的發展：人工智慧成像技術可以更準確地解釋X光、超音波和MRI，從而可以更早發現神經退化性疾病，而先進的分子診斷方法（包括基於PCR的檢測和次世代定序）可以更準確地識別疾病標誌物，反映了精準醫療的更廣泛趨勢。

研究也取得了顯著進展。某些曾被認為有望用於診斷神經退化性疾病的基因標記，根據新的研究已被否定，這凸顯了能夠跟上科學知識發展步伐的診斷技術的重要性。諸如用於牛腦病變(BSE) 監測的法律規範，證明了政府監管在疾病控制中的關鍵作用。這些項目凸顯了全面監測和可靠診斷對於維護動物和人類健康的重要性。

除了監測之外，生物標記發現、影像技術和神經行為測試的進步也持續改變診斷領域。這些進步支持早期療育和更完善的疾病管理，推動著該領域持續創新。公眾意識提升宣傳活動和計劃工作也發揮關鍵作用，推動研發投入。人們對診斷測試日益成長的興趣反映了獸醫學和人類醫學的通用目標：更有效地應對神經退化性疾病。

美國獸醫神經退化性疾病診斷市場：概述

  • 從產品來看，預計耗材、試劑和套件細分市場將在2024年佔據最大的收益佔有率，並在預測期內實現最快的複合年成長率。這種主導地位歸因於這些產品對於常規檢測至關重要，能夠為獸醫提供經濟高效、便捷且標準化的解決方案。這些產品常用於基因篩檢、生物標記檢測和免疫測量，而這些是診斷犬隻認知功能障礙等疾病的關鍵工具。
  • 根據診斷測試，影像學領域將在2024年佔據最大的市場佔有率，達到45.6%。該領域包括MRI和電腦斷層掃描等診斷影像學測試，其主導地位歸功於其能夠提供詳細的高解析度腦部影像，有助於檢測細微的結構變化。這些測試有助於區分重疊的臨床狀況，並且由於是非侵入性的，因此可以安全地重複使用。
  • 根據動物類型，預計伴侶動物將在2024年主導美國獸醫神經退化性疾病診斷行業，並在預測期內以最快的複合年成長率成長。該細分市場包括犬、貓和馬等動物，其主要驅動力是寵物擁有率的上升以及人們對犬退化性脊髓型頸椎病變、馬小腦萎縮和犬認知功能障礙等神經退化性疾病認知的提高。
  • 根據適應症，認知功能障礙細分市場預計將在2024年佔據最大的收益佔有率，並在預測期內以最快的複合年成長率成長。在美國，這些診斷測試主要用於診斷認知功能障礙綜合症（CDS），因為這類疾病在老年伴侶動物中非常普遍，尤其是狗和貓，它們構成了寵物飼養的最大群體。

目錄

第1章 分析方法與範圍

第2章執行摘要

第3章美國獸醫神經退化性疾病診斷市場：促進因素、趨勢與範圍

  • 市場聯動展望
    • 母市場
    • 附隨市場
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
    • 市場機會分析
    • 市場問題分析
  • 美國獸醫神經退化性疾病診斷市場：分析工具
    • 產業分析：波特五力分析
    • PESTEL分析
    • 法律規範
    • 定價分析
    • 寵物主人人口統計
    • 以主要國家和物種估計的動物數量（2024 年）

第4章美國獸醫神經退化性疾病診斷市場：按動物類型進行的估計和趨勢分析

  • 細分儀表板
  • 美國獸醫神經退化性疾病診斷市場趨勢分析（按動物類型）
  • 美國獸醫神經退化性疾病診斷市場規模及趨勢分析（依動物類型）（2018-2030）
  • 家畜
    • 羊
    • 牛
    • 其他
  • 伴侶動物
    • 犬科動物
    • 貓科
    • 馬
    • 其他

第5章美國獸醫神經退化性疾病診斷市場：診斷測試的估計和趨勢分析

  • 細分儀表板
  • 美國獸醫神經退化性疾病診斷市場趨勢分析（按診斷測試）
  • 美國獸醫神經退化性疾病診斷市場規模及趨勢分析（依診斷檢驗）（2018-2030）
  • 影像學診斷
    • MRI（磁振造影）
    • CT（電腦斷層掃描）
    • 其他
  • 生物標記診斷測試
    • 腦脊髓液（CSF）生物標記物
    • 血液中的生物標記
    • 其他
  • 其他

第6章美國獸醫神經退化性疾病診斷市場：按產品分類的估計和趨勢分析

  • 細分儀表板
  • 美國獸醫神經退化性疾病診斷市場趨勢分析（按產品）
  • 美國獸醫神經退化性疾病診斷市場規模與趨勢分析（按產品）（2018-2030）
    • 耗材、試劑和套件
    • 設備/裝備

第7章美國獸醫神經退化性疾病診斷市場：依適應症的估計與趨勢分析

  • 細分儀表板
  • 美國獸醫神經退化性疾病診斷市場趨勢（按適應症）
  • 美國獸醫神經退化性疾病診斷市場規模及趨勢分析（2018-2030）
    • 認知障礙
    • 小腦萎縮
    • 腦病變
    • 其他

第8章美國獸醫神經退化性疾病診斷市場：按最終用途的估計和趨勢分析

  • 細分儀表板
  • 美國獸醫神經退化性疾病診斷市場趨勢分析（按最終用途）
  • 美國獸醫神經退化性疾病診斷市場規模和趨勢分析（按最終用途）（2018-2030 年）
    • 獸醫診所
    • 獸醫診斷實驗室
    • 其他

第9章 競爭態勢

  • 市場參與企業分類
  • 企業市場分析/熱圖分析
  • 公司簡介
    • Zoetis Services LLC.
    • Vrac .
    • Life Diagnostics.
    • ACUVET BIOTECH
    • Merck &Co., Inc.
    • IDEXX Laboratories, Inc.
    • MI：RNA Diagnostics Ltd.
    • Mercodia AB
    • Antech Diagnostics, Inc.
    • Avacta Animal Health Limited
  • 戰略地圖
    • 企業合併與收購（M&A）
    • 商業夥伴關係與合作
    • 產品發布
    • 其他
  • 其他主要企業名單
Product Code: GVR-4-68040-603-5

U.S. Veterinary Neurodegenerative Disease Diagnostics Market Growth & Trends:

The U.S. veterinary neurodegenerative disease diagnostics market size is expected to reach USD 158.44 million by 2030, registering a CAGR of 7.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. The key factors driving the market growth are growing research initiatives, the rising prevalence of neurodegenerative diseases, and support initiatives. The increasing prevalence of neurodegenerative diseases in animals is fueling rapid growth in the veterinary diagnostics sector in the U.S. Conditions like Canine Cognitive Dysfunction (CCD) and Feline Cognitive Dysfunction (FCD) are becoming more widely recognized, with evidence suggesting that nearly 73% of senior dogs and 50% of senior cats exhibit signs of cognitive decline. This heightened awareness among pet owners and veterinarians has driven demand for early and accurate diagnostic tools.

Technological innovations are propelling this sector forward. AI-enhanced imaging techniques now offer more precise interpretation of X-rays, ultrasounds, and MRIs, enabling the earlier detection of neurodegenerative diseases. Meanwhile, advanced molecular diagnostics-including PCR-based assays and next-generation sequencing-provide more accurate identification of disease markers, reflecting a broader trend toward precision medicine.

Research has also evolved significantly. Specific genetic markers once considered promising for neurodegenerative disease diagnosis have been dismissed based on newer studies, underscoring the importance of adaptable diagnostic technologies that can keep pace with shifting scientific insights. Regulatory frameworks, such as those used in bovine spongiform encephalopathy (BSE) surveillance, demonstrate the crucial role of government oversight in disease control. These programs highlight how comprehensive monitoring and robust diagnostics are vital for maintaining animal and human health.

Beyond surveillance, progress in biomarker discovery, imaging technologies, and neurobehavioral testing continues to transform the diagnostic landscape. These advancements support earlier intervention and better disease management, driving the sector toward continuous innovation. Public awareness campaigns and advocacy efforts have also played a pivotal role, boosting investment in research and development. This surge of interest in diagnostic testing reflects a shared priority-across both veterinary and human medicine-to address neurodegenerative diseases more effectively.

U.S. Veterinary Neurodegenerative Disease Diagnostics Market Report Highlights:

  • Based on product, consumables, reagents, and kits segment held the largest revenue share in 2024, and is expected to grow at the fastest CAGR over the forecast period. This dominance can be attributed to these products being essential for routine testing, offering cost-effective, convenient, and standardized solutions for veterinarians. These products are frequently used in genetic screening, biomarker assays, and immunoassays and are key tools for diagnosing conditions like canine cognitive dysfunction.
  • Based on diagnostic tests, the imaging segment held the largest market share of 45.6% in 2024. This segment consists of imaging diagnostic tests such as MRI and CT scans, whose dominance can be attributed to their ability to provide detailed, high-resolution images of the brain, which aid in detecting subtle structural changes. They help differentiate between overlapping clinical signs and are non-invasive, making them safe for repeated use.
  • Based on animal type, the companion animal segment dominated the U.S. veterinary neurodegenerative disease diagnostics industry in 2024 and is also expected to grow at the fastest CAGR over the forecast period. This segment, which includes animals such as canines, felines, equines, etc., is mainly driven by rising pet ownership and increased awareness of neurodegenerative conditions like degenerative myelopathy in dogs, cerebellar abiotrophy in horses, and canine cognitive dysfunction.
  • Based on indication, the cognitive dysfunction segment held the largest revenue share in 2024 and is expected to grow at the fastest CAGR over the forecast period. In the U.S., these diagnostic tests are most commonly conducted for cognitive dysfunction syndrome (CDS) primarily because it is highly prevalent among aging companion animals, especially dogs and cats, constituting the largest segment of pet ownership.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources
    • 1.3.4. Primary Research
  • 1.4. Information/Data Analysis
  • 1.5. Market Formulation & Visualization
  • 1.6. Data Validation & Publishing
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis
    • 1.7.2. Global Market: CAGR Calculation
  • 1.8. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Veterinary Neurodegenerative Disease Diagnostics Market Variable Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market
    • 3.1.2. Ancillary Market
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growing Research Initiatives
      • 3.2.1.2. Rising Prevalence of Neurodegenerative Diseases
      • 3.2.1.3. Support Initiatives
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Lack of standardized regulations
      • 3.2.2.2. Lack of awareness in developing economies
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenge Analysis
  • 3.3. U.S. Veterinary Neurodegenerative Disease Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitution
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political & Legal landscape
      • 3.3.2.2. Economic and Social landscape
      • 3.3.2.3. Technological landscape
      • 3.3.2.4. Environmental landscape
    • 3.3.3. Regulatory Framework
    • 3.3.4. Pricing Analysis
    • 3.3.5. Pet Ownership Demographics
    • 3.3.6. Estimated Animal Population by key countries, key species, 2024

Chapter 4. U.S. Veterinary Neurodegenerative Disease Diagnostics Market: Animal Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Veterinary Neurodegenerative Disease Diagnostics Market: Animal type Movement Analysis
  • 4.3. U.S. Veterinary Neurodegenerative Disease Diagnostics Market Size & Trend Analysis, by animal type, 2018 to 2030 (USD Million)
  • 4.4. Livestock
    • 4.4.1. Livestock Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.2. Sheep
      • 4.4.2.1. Sheep Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.3. Cattle
      • 4.4.3.1. Cattle Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.4. Others
      • 4.4.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Companion
    • 4.5.1. Companion Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.2. Canine
      • 4.5.2.1. Canine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.3. Feline
      • 4.5.3.1. Feline Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.4. Equine
      • 4.5.4.1. Equine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.5. Others
      • 4.5.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. Veterinary Neurodegenerative Disease Diagnostics Market: Diagnostic Tests Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Veterinary Neurodegenerative Disease Diagnostics Market: Diagnostic Tests Movement Analysis
  • 5.3. U.S. Veterinary Neurodegenerative Disease Diagnostics Market Size & Trend Analysis, by Diagnostic Tests, 2018 to 2030 (USD Million)
  • 5.4. Imaging
    • 5.4.1. Imaging Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.2. MRI (Magnetic Resonance Imaging)
      • 5.4.2.1. MRI (Magnetic Resonance Imaging) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.3. CT (Computed Tomography)
      • 5.4.3.1. CT (Computed Tomography) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.4. Others
      • 5.4.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Biomarker Diagnostic Tests
    • 5.5.1. Biomarker Diagnostic Tests Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.5.2. CSF (Cerebrospinal Fluid) biomarkers
      • 5.5.2.1. CSF (Cerebrospinal Fluid) biomarkers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.5.3. Blood-based biomarkers
      • 5.5.3.1. Blood-based biomarkers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.5.4. Others
      • 5.5.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. U.S. Veterinary Neurodegenerative Disease Diagnostics Market: By Product Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Veterinary Neurodegenerative Disease Diagnostics Market: By Product Movement Analysis
  • 6.3. U.S. Veterinary Neurodegenerative Disease Diagnostics Market Size & Trend Analysis, by product, 2018 to 2030 (USD Million)
    • 6.3.1. Consumables, Reagents & Kits
      • 6.3.1.1. Consumables, Reagents & Kits Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. Equipment & Instruments
      • 6.3.2.1. Equipment & Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. U.S. Veterinary Neurodegenerative Disease Diagnostics Market: By Indication Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. U.S. Veterinary Neurodegenerative Disease Diagnostics Market: By Indication, Movement Analysis
  • 7.3. U.S. Veterinary Neurodegenerative Disease Diagnostics Market Size & Trend Analysis, by Indication, 2018 to 2030 (USD Million)
    • 7.3.1. Cognitive Dysfunction
      • 7.3.1.1. Cognitive Dysfunction Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. Cerebellar Abiotrophy
      • 7.3.2.1. Cerebellar Abiotrophy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Spongiform Encephalopathies
      • 7.3.3.1. Spongiform Encephalopathies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. Others
      • 7.3.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. U.S. Veterinary Neurodegenerative Disease Diagnostics Market: By End Use Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. U.S. Veterinary Neurodegenerative Disease Diagnostics Market: By End Use Movement Analysis
  • 8.3. U.S. Veterinary Neurodegenerative Disease Diagnostics Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
    • 8.3.1. Veterinary Hospitals and Clinics
      • 8.3.1.1. Veterinary Hospitals and Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.2. Veterinary Diagnostic Laboratories
      • 8.3.2.1. Veterinary Diagnostic Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.3. Others
      • 8.3.3.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Market Participant Categorization
  • 9.2. Company Market Position Analysis/ Heat Map Analysis
  • 9.3. Company Profiles
    • 9.3.1. Zoetis Services LLC.
      • 9.3.1.1. Participant's Overview
      • 9.3.1.2. Financial Performance
      • 9.3.1.3. Product Benchmarking
      • 9.3.1.4. Strategic Initiatives
    • 9.3.2. Vrac .
      • 9.3.2.1. Participant's Overview
      • 9.3.2.2. Financial Performance
      • 9.3.2.3. Product Benchmarking
      • 9.3.2.4. Strategic Initiatives
    • 9.3.3. Life Diagnostics.
      • 9.3.3.1. Participant's Overview
      • 9.3.3.2. Financial Performance
      • 9.3.3.3. Product Benchmarking
      • 9.3.3.4. Strategic Initiatives
    • 9.3.4. ACUVET BIOTECH
      • 9.3.4.1. Participant's Overview
      • 9.3.4.2. Financial Performance
      • 9.3.4.3. Product Benchmarking
      • 9.3.4.4. Strategic Initiatives
    • 9.3.5. Merck & Co., Inc.
      • 9.3.5.1. Participant's Overview
      • 9.3.5.2. Financial Performance
      • 9.3.5.3. Product Benchmarking
      • 9.3.5.4. Strategic Initiatives
    • 9.3.6. IDEXX Laboratories, Inc.
      • 9.3.6.1. Participant's Overview
      • 9.3.6.2. Financial Performance
      • 9.3.6.3. Product Benchmarking
      • 9.3.6.4. Strategic Initiatives
    • 9.3.7. MI:RNA Diagnostics Ltd.
      • 9.3.7.1. Participant's Overview
      • 9.3.7.2. Financial Performance
      • 9.3.7.3. Product Benchmarking
      • 9.3.7.4. Strategic Initiatives
    • 9.3.8. Mercodia AB
      • 9.3.8.1. Participant's Overview
      • 9.3.8.2. Financial Performance
      • 9.3.8.3. Product Benchmarking
      • 9.3.8.4. Strategic Initiatives
    • 9.3.9. Antech Diagnostics, Inc.
      • 9.3.9.1. Participant's Overview
      • 9.3.9.2. Financial Performance
      • 9.3.9.3. Product Benchmarking
      • 9.3.9.4. Strategic Initiatives
    • 9.3.10. Avacta Animal Health Limited
      • 9.3.10.1. Participant's Overview
      • 9.3.10.2. Financial Performance
      • 9.3.10.3. Product Benchmarking
      • 9.3.10.4. Strategic Initiatives
  • 9.4. Strategy Mapping
    • 9.4.1. Mergers & Acquisitions
    • 9.4.2. Partnerships & Collaborations
    • 9.4.3. Product launch
    • 9.4.4. Others
  • 9.5. List of other key players

List of Tables

  • Table 1 List of secondary sources
  • Table 2 U.S. Veterinary Neurodegenerative Disease Diagnostics Market, by Animal type, 2018 - 2030 (USD Million)
  • Table 3 U.S. Veterinary Neurodegenerative Disease Diagnostics Market, by Indication, 2018 - 2030 (USD Million)
  • Table 4 U.S. Veterinary Neurodegenerative Disease Diagnostics Market, by Diagnostic Tests, 2018 - 2030 (USD Million)
  • Table 5 U.S. Veterinary Neurodegenerative Disease Diagnostics Market, by Product, 2018 - 2030 (USD Million)
  • Table 6 U.S. Veterinary Neurodegenerative Disease Diagnostics Market, by End Use, 2018 - 2030 (USD Million)
  • Table 7 Company Overview
  • Table 8 Product Benchmarking
  • Table 9 Financial Performance
  • Table 10 Strategic Initiatives

List of Figures

  • Fig. 1 Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. Veterinary Neurodegenerative Disease Diagnostics Market revenue, 2018 - 2030 (USD Million)
  • Fig. 10 U.S. Veterinary Neurodegenerative Disease Diagnostics Market snapshot
  • Fig. 11 U.S. Veterinary Neurodegenerative Disease Diagnostics Market driver impact
  • Fig. 12 U.S. Veterinary Neurodegenerative Disease Diagnostics Market restraint impact
  • Fig. 13 U.S. Veterinary Neurodegenerative Disease Diagnostics animal type key takeaways (USD Million)
  • Fig. 14 U.S. Veterinary Neurodegenerative Disease Diagnostics Market: animal Type movement analysis
  • Fig. 15 Companion market, 2018 - 2030 (USD Million)
  • Fig. 16 canine market, 2018 - 2030 (USD Million)
  • Fig. 17 Feline market, 2018 - 2030 (USD Million)
  • Fig. 18 Equine market, 2018 - 2030 (USD Million)
  • Fig. 19 Others market, 2018 - 2030 (USD Million)
  • Fig. 20 Livestock market, 2018 - 2030 (USD Million)
  • Fig. 21 Sheep market, 2018 - 2030 (USD Million)
  • Fig. 22 Cattle market, 2018 - 2030 (USD Million)
  • Fig. 23 Others market, 2018 - 2030 (USD Million)
  • Fig. 24 U.S. Veterinary Neurodegenerative Disease Diagnostics Market Product Key Takeaways (USD Million)
  • Fig. 25 U.S. Veterinary Neurodegenerative Disease Diagnostics Market: product movement analysis
  • Fig. 26 Consumables, Reagents & Kits market, 2018 - 2030 (USD Million)
  • Fig. 27 Equipment & Instruments market, 2018 - 2030 (USD Million)
  • Fig. 28 U.S. Veterinary Neurodegenerative Disease Diagnostics Market Diagnostic Tests key takeaways (USD Million)
  • Fig. 29 U.S. Veterinary Neurodegenerative Disease Diagnostics Market: Diagnostic Tests movement analysis
  • Fig. 30 Imaging market, 2018 - 2030 (USD Million)
  • Fig. 31 MRI (Magnetic Resonance Imaging) market, 2018 - 2030 (USD Million)
  • Fig. 32 CT (Computed Tomography) market, 2018 - 2030 (USD Million)
  • Fig. 33 Others market, 2018 - 2030 (USD Million)
  • Fig. 34 Biomarker Diagnostic Tests market, 2018 - 2030 (USD Million)
  • Fig. 35 CSF (Cerebrospinal Fluid) biomarkers market, 2018 - 2030 (USD Million)
  • Fig. 36 Blood-based biomarkers market, 2018 - 2030 (USD Million)
  • Fig. 37 Others market, 2018 - 2030 (USD Million)
  • Fig. 38 Others market, 2018 - 2030 (USD Million)
  • Fig. 39 U.S. Veterinary Neurodegenerative Disease Diagnostics Market Indication Key Takeaways (USD Million)
  • Fig. 40 U.S. Veterinary Neurodegenerative Disease Diagnostics Market: Indication movement analysis
  • Fig. 41 Cognitive Dysfunction market, 2018 - 2030 (USD Million)
  • Fig. 42 Cerebellar Abiotrophy Flow Assays market, 2018 - 2030 (USD Million)
  • Fig. 43 Spongiform Encephalopathies market, 2018 - 2030 (USD Million)
  • Fig. 44 Others market, 2018 - 2030 (USD Million)
  • Fig. 45 Veterinary Neurodegenerative Disease Diagnostics Market by End Use key takeaways (USD Million)
  • Fig. 46 U.S. Veterinary Neurodegenerative Disease Diagnostics Market: by End Use movement analysis
  • Fig. 47 Veterinary Diagnostic Laboratories market, 2018 - 2030 (USD Million)
  • Fig. 48 Veterinary Hospitals and Clinics market, 2018 - 2030 (USD Million)
  • Fig. 49 Others market, 2018 - 2030 (USD Million)
  • Fig. 50 Market participant categorization